In 2013, a controlled study conducted by Umpierrez et al. [17] showed that treatment with sitagliptin alone or in combination with basal insulin was as safe and effective as a basal-bolus insulin regimen for managing hyperglycaemia in patients with T2D in hospital setting. The gene discussed is INS; the disease is Hyperglycemia.